Dynamic Regulation of Tumor Growth and Metastasis by Heparan Sulfate Glycosaminoglycans

Dongfang Liu; Zachary Shriver; Yiwei Qi; Ganesh Venkataraman; Ram Sasisekharan

doi:10.1055/s-2002-20565

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2002; 28(1): 67-78
DOI: 10.1055/s-2002-20565

Dynamic Regulation of Tumor Growth and Metastasis by Heparan Sulfate Glycosaminoglycans

Dongfang Liu¹ , Zachary Shriver¹ , Yiwei Qi¹ , Ganesh Venkataraman² , Ram Sasisekharan^1, ³

¹Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology, Cambridge, Massachusetts
²Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, Massachusetts
³Center for Biomedical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts

Abstract

ABSTRACT

This article focuses on the emerging views and concepts concerning the role of cell surface and extracellular heparan sulfate-like glycosaminoglycans (HSGAGs) in tumor biology. HSGAGs, found ubiquitously both at the cell surface and in the extracellular matrix (ECM), play a critical role in regulating tumor initiation, progression, and metastasis. The diverse biological functions of HSGAGs include the regulation of coagulation, growth factor signaling, cell adhesion, proliferation, and mobility. HSGAGs, depending on their location (anchored at the cell surface or soluble as free GAGs), the signaling molecules they associate with, and their fine structures, can either promote or inhibit the tumorigenic process.

KEYWORD

Heparan sulfate-like glycosaminoglycans - extracellular matrix - metastasis - anticoagulation

Volltext

Referenzen

REFERENCES

1 Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1998. CA Cancer J Clin . 1998; 48 6-29
2 Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1999. CA Cancer J Clin . 1999; 49 8-31, 1
3 Cotran R, Kumar V, Robbins S L. Pathologic Basis of Disease. Philadelphia: Saunders 1999
4 Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell . 1990; 61 759-767
5 Kinzler K W, Vogelstein B. Lessons from hereditary colorectal cancer. Cell . 1996; 87 159-170
6 Ilyas M, Tomlinson I P. Genetic pathways in colorectal cancer. Histopathology . 1996; 28 389-399
7 Kinzler K W, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature . 1997; 386 761-763
8 Weinberg R. How cancer arises. Sci Am . 1996; 275 62-70
9 Hunter T. Oncoprotein networks. Cell . 1997; 88 333-346
10 Nakamura Y, Nishisho I, Kinzler K W. Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial polyposis coli) patients and in sporadic colorectal tumors. Tohoku J Exp Med . 1992; 168 141-147
11 O'Reilly M S, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med . 1996; 2 689-692
12 O'Reilly M S, Boehm T, Shing Y. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell . 1997; 88 277-285
13 Pluda J M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol . 1997; 24 203-218
14 Pluda J M, Parkinson D R. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer . 1996; 78 680-687
15 Sanderson R D. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol . 2001; 12 89-98
16 Price J T, Bonovich M T, Kohn E C. The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol . 1997; 32 175-253
17 Ziober B L, Lin C S, Kramer R H. Laminin-binding integrins in tumor progression and metastasis. Semin Cancer Biol . 1996; 7 119-128
18 Stetler-Stevenson W G, Yu A E. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol . 2001; 11 143-153
19 Chambers A F, Matrisian L M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst . 1997; 89 1260-1270
20 Hulett M D, Freeman C, Hamdorf B J. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med . 1999; 5 803-809
21 Vlodavsky I, Friedmann Y, Elkin M. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nature Med . 1999; 5 793-802
22 Borsig L, Wong R, Feramisco J. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA . 2001; 98 3352-3357
23 Zacharski L R, Ornstein D L, Mamourian A C. Low-molecular-weight heparin and cancer. Semin Thromb Hemost . 2000; 26 69-77
24 Zacharski L R, Ornstein D L. Heparin and cancer. Thromb Haemost . 1998; 80 10-23
25 Zacharski L R, Meehan K R, Algarra S M, Calvo F A. Clinical trials with anticoagulant and antiplatelet therapies. Cancer Metastasis Rev . 1992; 11 421-431
26 Hejna M, Raderer M, Zielinski C C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst . 1999; 91 22-36
27 Engelberg H. Actions of heparin that may affect the malignant process. Cancer . 1999; 85 257-272
28 Sasisekharan R, Venkataraman G. Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol . 2000; 4 626-631
29 Sasisekharan R, Ernst S, Venkararaman V. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans. Angiogenesis . 1997; 1 45-54
30 Lin X, Perrimon N. Role of heparan sulfate proteoglycans in cell-cell signaling in drosophila Matrix Biol . 2000; 19 303-307
31 Lin X, Buff E M, Perrimon N, Michelson A M. Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development . 1999; 126 3715-3723
32 Sasisekharan R, Moses M A, Nugent M A, Cooney C L, Langer R. Heparinase inhibits neovascularization. Proc Natl Acad Sci USA . 1994; 91 1524-1528
33 Jacques L B. Heparin: an old drug with a new paradigm. Science . 1979; 206 528-533
34 Bernfield M, Gotte M, Park P W. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem . 1999; 68 729-777
35 Humphries D E, Wong G W, Friend D S. Heparin is essential for the storage of specific granule proteases in mast cells. Nature . 1999; 400 769-772
36 Forsberg E, Pejler G, Ringvall M. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature . 1999; 400 773-776
37 Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature . 2000; 404 725-728
38 Lin X, Perrimon N. Dally cooperates with Drosophila Frizzled 2 to transduce Wingless signalling. Nature . 1999; 400 281-284
39 Carey D J. Syndecans: multifunctional cell-surface co-receptors. Biochem J . 1997; 327 1-16
40 Shriver Z, Raman R, Venkataraman G. From the cover: sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site. Proc Natl Acad Sci USA . 2000; 97 10359-10364
41 Pye D A, Vives R R, Hyde P, Gallagher J T. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology . 2000; 10 1183-1192
42 Pye D A, Vives R R, Turnbull J E, Hyde P, Gallagher J T. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem . 1998; 273 22936-22942
43 Guimond S E, Turnbull J E. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr Biol . 1999; 9 1343-1346
44 Saoncella S, Echtermeyer F, Denhez F. Syndecan-4 signals cooperate with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc Natl Acad Sci USA . 1999; 96 2805-2810
45 Woods A, Longley R L, Tumova S, Couchman J R. Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts. Arch Biochem Biophys . 2000; 374 66-72
46 Woods A, Couchman J R. Syndecans: synergistic activators of cell adhesion. Trends Cell Biol . 1998; 8 189-192
47 Giuffre L, Cordey A S, Monai N. Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans. J Cell Biol . 1997; 136 945-956
48 Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest . 1998; 101 877-889
49 Sasaki T, Larsson H, Kreuger J. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J . 1999; 18 6240-6248
50 Guimond S, Maccarana M, Olwin B B, Lindahl U, Rapraeger A C. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem . 1993; 268 23906-23914
51 Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor [published erratum appears in J Biol Chem 1994;269:3903]. J Biol Chem . 1993; 268 23898-23905
52 Lyon M, Deakin J A, Mizuno K, Nakamura T, Gallagher J T. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem . 1994; 269 11216-11223
53 Pellegrini L, Burke D F, von Delft F, Mulloy B, Blundell T L. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature . 2000; 407 1029-1034
54 Schlessinger J, Plotnikov A N, Ibrahimi O A. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell . 2000; 6 743-750
55 Plotnikov A N, Schlessinger J, Hubbard S R, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell . 1999; 98 641-650
56 Venkataraman G, Shriver Z, Davis J C, Sasisekharan R. Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans. Proc Natl Acad Sci USA . 1999; 96 1892-1897
57 Caldwell E E, Nadkarni V D, Fromm J R, Linhardt R J, Weiler J M. Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Int J Biochem Cell Biol . 1996; 28 203-216
58 Hileman R E, Fromm J R, Weiler J M, Linhardt R J. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays . 1998; 20 156-167
59 Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med . 1996; 28 63-67
60 McCormick C, Duncan G, Goutsos K T, Tufaro F. The putative tumor suppressors EXTI and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA . 2000; 97 668-673
61 Pilia G, Hughes-Benzie R M, MacKenzie A. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genet . 1996; 12 241-247
62 Jayson G C, Lyon M, Paraskeva C. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem . 1998; 273 51-57
63 Nackaerts K, Verbeken E, Deneffe G. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer . 1997; 74 335-345
64 Sharma B, Handler M, Eichstetter I. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest . 1998; 102 1599-1608
65 Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell . 1995; 6 559-576
66 Kleeff J, Ishiwata T, Kumbasar A. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest . 1998; 102 1662-1673
67 Redini F, Moczar E, Poupon M F. Cell surface glycosaminoglycans of rat rhabdomyosarcoma lines with different metastatic potentials and of non-malignant rat myoblasts. Biochim Biophys Acta . 1986; 883 98-105
68 Kure S, Yoshie O, Aso H. Metastatic potential of murine B16 melanoma correlates with reduced surface heparan sulfate glycosaminoglycan. Jpn J Cancer Res . 1987; 78 1238-1245
69 Filmus J. Glypicans in growth control and cancer. Glycobiology . 2001; 11 19R-23R
70 Adatia R, Albini A, Carlone S. Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann Oncol . 1997; 8 1257-1261
71 Filla M S, Dam P, Rapraeger A C. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol . 1998; 174 310-321
72 Rapraeger A C, Krufka A, Olwin B B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science . 1991; 252 1705-1708
73 Lundin L, Larsson H, Kreuger J. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem . 2000; 275 24653-24660
74 Turnbull J E, Fernig D G, Ke Y, Wilkinson M C, Gallagher J T. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem . 1992; 267 10337-10341
75 Gallagher J T. Structure-activity relationship of heparan sulphate. Biochem Soc Trans . 1997; 25 1206-1209
76 Fannon M, Forsten K E, Nugent M A. Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. Biochemistry . 2000; 39 1434-1445
77 Gengrinovitch S, Berman B, David G. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem . 1999; 274 10816-10822
78 Folkman J, Langer R, Linhardt R J, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science . 1983; 221 719-725
79 Brickman Y G, Nurcombe V, Ford M D. Structural comparison of fibroblast growth factor-specific heparan sulfates derived from a growing or differentiating neuroepithelial cell line. Glycobiology . 1998; 8 463-471
80 Jayson G C, Gallagher J T. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer . 1997; 75 9-16
81 Karumanchi S A, Jha V, Ramchandran R. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell . 2001; 7 811-822
82 Woods A, Oh E S, Couchman J R. Syndecan proteoglycans and cell adhesion. Matrix Biol . 1998; 17 477-483
83 Tovari J, Paku S, Raso E. Role of sinusoidal heparan sulfate proteoglycan in liver metastasis formation. Int J Cancer . 1997; 71 825-831
84 Venkataraman G, Shriver Z, Raman R, Sasisekharan R. Sequencing complex polysaccharides. Science . 1999; 286 537-542
85 Keiser N, Venkataraman G, Shriver Z, Sasisekharan R. Direct isolation and sequencing of specific protein-binding glycosaminoglycans. Nature Med . 2001; 7 123-128
86 Sears P, Wong C H. Toward automated synthesis of oligosaccharides and glycoproteins. Science . 2001; 291 2344-2350
87 Plante O J, Palmacci E R, Seeberger P H. Automated solid-phase synthesis of oligosaccharides. Science . 2001; 291 1523-1527
88 Aikawa J, Esko J D. Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAc N-deacetylase/N-sulfotransferase family. J Biol Chem . 1999; 274 2690-2695
89 Kobayashi M, Habuchi H, Yoneda M, Habuchi O, Kimata K. Molecular cloning and expression of Chinese hamster ovary cell heparan-sulfate 2-sulfotransferase. J Biol Chem . 1997; 272 13980-13985
90 Kobayashi M, Sugumaran G, Liu J. Molecular cloning and characterization of a human uronyl 2-sulfotransferase that sulfates iduronyl and glucuronyl residues in dermatan/chondroitin sulfate. J Biol Chem . 1999; 274 10474-10480
91 Kojima T, Shworak N W, Rosenberg R D. Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem . 1992; 267 4870-4877
92 Shworak N W, Liu J, Fritze L M. Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem . 1997; 272 28008-28019
93 Shworak N W, Liu J, Petros L M. Multiple isoforms of heparan sulfate d-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cDNAs and identification of distinct genomic loci. J Biol Chem . 1999; 274 5170-5184
94 Sugahara K, Kitagawa H. Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. Curr Opin Struct Biol . 2000; 10 518-527
95 Bullock S L, Fletcher J M, Beddington R S, Wilson V A. Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev . 1998; 12 1894-1906
96 Alexander C M, Reichsman F, Hinkes M T. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nature Genet . 2000; 25 329-332